MODAG
Torsten Matthias is an accomplished professional with extensive experience in the biotechnology and diagnostics sectors. As the Founder and President of AESKU.GROUP since 2000, Torsten has focused on developing innovative products for the early detection and diagnosis of autoimmune diseases. In addition, as a Co-Funder of MODAG since 2014, Torsten works on novel therapeutic approaches for neurodegenerative diseases. Prior to these ventures, Torsten served as the Head of the Research and Development Department at ORGENTEC Diagnostika GmbH from 1992 to 1999, where contributions included the implementation of molecular biology in research and quality control, as well as marketing and procurement of autoimmune products. Torsten holds a Doctor's Degree in Biochemistry and Gene Technology from Bielefeld University and a Doctor's Degree in Physical Biochemistry from Technische Universität Dresden.
This person is not in the org chart
This person is not in any teams
MODAG
MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Their first objective is to demonstrate clinical proof-of-concept with their lead compound anle138b in Multiple System Atrophy (MSA) seeking to halt the progression and provide a firstdisease-modifying therapeutic.This success will allow us to apply their technology to similar diseases such as Parkinson’s and other synucleinopathies with the goal of dissolving disease-related intra-cellular oligomers, thereby reducing their toxic properties.MODAG is comprised of experts in the clinical research and neurodegenerative disease space and supported by grants from leading patient organizations including the Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson’s UK.